<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="207814">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00382824</url>
  </required_header>
  <id_info>
    <org_study_id>LaheyC</org_study_id>
    <nct_id>NCT00382824</nct_id>
  </id_info>
  <brief_title>Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP)</brief_title>
  <official_title>Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP): A Multicenter, Randomized, Placebo-controlled, Double Blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lahey Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lahey Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical syndrome of PSP responds poorly to all available forms of therapy used in
      Parkinson's Disease (PD). Currently, no effective treatment exists. Coenzyme Q10 in high
      doses has been shown to be a beneficial therapy in PD and might possibly be a beneficial
      therapy for PSP. This study will compare the efficacy, safety and tolerability of Coenzyme
      Q10 versus placebo in patients with atypical parkinsonian syndrome, progressive supranuclear
      palsy (PSP).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed as a multicenter randomized, placebo-controlled, double blind trial.
      Up to 60 patients with PSP will be enrolled at several centers in the United States
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Functional decline</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional ability</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Progressive Supranuclear Palsy</condition>
  <condition>Atypical Parkinsonism</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CoenzymeQ10</intervention_name>
    <description>active drug</description>
    <other_name>CoQ10</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients fulfilling the diagnostic criteria of PSP/diagnosed within the past 5 years

          -  Either vertical supranuclear palsy or both slowing of vertical saccades

          -  Prominent postural instability with falls in the first year of disease onset

          -  No evidence of other diseases that could explain the foregoing features

        Exclusion Criteria:

          -  Current or previous therapeutic use of CoQ10

          -  Parkinsonism due to drugs

          -  History of pallidotomy, thalamotomy, active deep brain stimulator or fetal tissue
             transplant

          -  History of active epilepsy, stroke, structural brain disease

          -  Use of methylphenidate hydrochloride, cinnarizine, reserpine, amphetamines, or
             monoamine oxidase-A inhibitors within 3 months before the baseline visit.

          -  Active cancer or cancer undergoing treatment

          -  Participation in other drug studies or the use of other investigational drugs within
             30 days before screening.

          -  Known hypersensitivity to Coenzyme Q10.

          -  Pregnant, planning a pregnancy or nursing woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana Apetauerova, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lahey Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.wemove.org</url>
  </link>
  <link>
    <url>http://www.psp.org</url>
  </link>
  <link>
    <url>http://www.lahey.org</url>
  </link>
  <verification_date>August 2015</verification_date>
  <lastchanged_date>August 4, 2015</lastchanged_date>
  <firstreceived_date>September 28, 2006</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Progressive Supranuclear Palsy</keyword>
  <keyword>Atypical Parkinsonism</keyword>
  <keyword>CoQ10</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paralysis</mesh_term>
    <mesh_term>Parkinsonian Disorders</mesh_term>
    <mesh_term>Supranuclear Palsy, Progressive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coenzyme Q10</mesh_term>
    <mesh_term>Ubiquinone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
